Clinical trials: Cancers Expressing HER-2 and/or CEA
Cancer
A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)
Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens.
- Trial name
- NCT00647114
- Testing
- V930, V932
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancers Expressing HER-2 and/or CEA
V930 First in Man (FIM) Study (V930-002)(COMPLETED)
To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as intramuscular injections followed by electrostimulation in cancer patients.
- Trial name
- NCT00250419
- Testing
- V930
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC